3rd Department of Medicine, Institute for Medicine, Medical and Health Science Center, University of Debrecen, Hungary.
Pathol Oncol Res. 2012 Jan;18(1):43-8. doi: 10.1007/s12253-011-9414-7. Epub 2011 Jun 14.
The addition of rituximab to conventional chemotherapy has significantly improved the treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment response and survival data can be observed independently from the International Prognostic Index scores. The current study evaluated the impact of Fc-gamma-receptor IIIa polymorphism and gene expression profile on the response of DLBCL patients to R-CHOP therapy as well as on their survival results. Fifty-one patients were involved, thirty-two females, nineteen males, their median age was 53.1 years. The FCGR3A polymorphism at the 158. amino acid position determined with PCR method showed the following results: VV: 12 cases (23.5%), VF: 29 cases (56.8%) and FF: 10 cases (19.6%), respectively. There was no significant difference between the treatment responses of the three groups. The event-free survival data were less favorable in the F-allele carriers than in V/V homozygous patients, but without any significancy, and the overall survival curves were almost the same. As for the gene expression profile, 20 patients' biopsy specimens showed germinal center and 31 showed non-germinal center characteristics. Treatment results did not differ from each other in the two groups. Both the event-free and the overall survival data were more favorable in the GC group, however the differences were not significant. Our results contest the predictive value of Fc-gamma-receptor IIIa polymorphism and gene expression profile in diffuse large B-cell lymphoma.
利妥昔单抗联合常规化疗显著改善了弥漫性大 B 细胞淋巴瘤的治疗效果。然而，治疗反应和生存数据的差异可以独立于国际预后指数评分观察到。本研究评估了 Fc-γ-受体 IIIa 多态性和基因表达谱对 DLBCL 患者对 R-CHOP 治疗反应以及生存结果的影响。共纳入 51 例患者，其中女性 32 例，男性 19 例，中位年龄为 53.1 岁。采用 PCR 方法检测 158 位氨基酸位置的 FCGR3A 多态性，结果如下：VV：12 例（23.5%），VF：29 例（56.8%）和 FF：10 例（19.6%）。三组治疗反应无显著差异。与 V/V 纯合子患者相比，F 等位基因携带者的无事件生存数据较差，但无显著差异，总生存曲线几乎相同。至于基因表达谱，20 例患者的活检标本显示生发中心，31 例显示非生发中心特征。两组的治疗结果无差异。GC 组的无事件生存和总生存数据均更为有利，但差异无统计学意义。我们的结果对 Fc-γ-受体 IIIa 多态性和基因表达谱在弥漫性大 B 细胞淋巴瘤中的预测价值提出了质疑。
